English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 5 February 2026, 13:00 HKT/SGT
Share:
    

Source: Annature
Annature Launches 21 CFR Part 11 Compliant Digital Signatures to Support FDA-Regulated Organisations

BRISBANE, AUS, Feb 5, 2026 - (ACN Newswire) - Annature, Australia's leading eSignature and Identity verification provider, has announced the release of its 21 CFR Part 11 compliant electronic signature module, enabling organisations operating in FDA‑regulated environments to execute electronic records with confidence.

The new capability ensures Annature customers can meet the U.S. Food and Drug Administration's requirements for electronic records and electronic signatures under 21 CFR Part 11, a regulation that governs data integrity, signer authentication, and auditability across industries such as life sciences, pharmaceuticals, biotechnology, and clinical research.

The release has been driven by growing demand from U.S.-based and multinational organisations seeking a modern, compliant alternative to legacy eSignature platforms. Several customers operating in regulated environments have already transitioned to Annature as part of broader digital transformation initiatives, prompting the company to formally introduce Part 11 support as part of its international product roadmap.

"As we continue to grow globally, it's critical that Annature supports the regulatory frameworks our customers operate under," said Corey Cacic, CEO of Annature. "Our 21 CFR Part 11 module allows organisations subject to FDA requirements to use Annature with confidence, knowing their electronic signatures meet the necessary compliance standards."

The module introduces controls aligned with Part 11 expectations, including secure signer authentication, tamper‑evident audit trails, and strong linkage between electronic signatures and the records they relate to. These features ensure electronic signatures executed through Annature can be relied upon in regulated workflows and during regulatory review.

Kim Steel, Founder and Managing Director of SAPRO - a boutique CRO supporting niche biotech and pharmaceutical companies with commercially sponsored Phase I-III full-service clinical trials has welcomed the release.

"For organisations operating in regulated environments, compliance with 21 CFR Part 11 is not optional - it is fundamental," said Steel. "It is encouraging to see Annature, an Australian technology provider supporting international regulatory requirements that are critical to our industry and our clients. Solutions like this enable sponsors to operate confidently on a global stage, without reliance on outdated or overly complex legacy systems, while remaining inspection and audit-ready at all times."

The launch further strengthens Annature's position as a global‑ready eSignature platform, supporting organisations that operate across jurisdictions with varying compliance obligations. The 21 CFR Part 11 module is available now and can be enabled for customers who require FDA‑compliant electronic signatures.

About Annature

Annature is Australia's leading eSignature and Identity verification provider, trusted by over 6,700 businesses. With a Pay as you go model and deep integration across the business app ecosystem, Annature delivers secure, affordable, and locally supported solutions for professionals across the country. Annature's growing product suite also includes integrated payments and compliance features designed to support both domestic and international regulatory requirements.

https://www.annature.com.au

CONTACT:
Name: Corey Cacic
Email: corey@annature.com.au

SOURCE: Annature



Topic: Press release summary
Source: Annature

Sectors: Digitalization, Legal & Compliance
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Tenstorrent Unveils TT-QuietBox(TM) 2, the First RISC-V AI Workstation With a Fully Open-Source Stack to Deliver Teraflop-Class Inference  
Mar 12, 2026 00:00 HKT/SGT
Yuexiu REIT Maintains Operational Resilience, Revenue Exceeds RMB1.8 Billion in 2025  
Mar 11, 2026 19:16 HKT/SGT
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis  
Wednesday, March 11, 2026 7:15:00 PM
MarketingPulse and eTailingPulse open next Thursday  
Mar 11, 2026 16:54 HKT/SGT
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting   
Wednesday, March 11, 2026 11:07:00 AM
JOYY Reports 4Q and FY2025 Financial Results: Q4 Revenue Returns to YoY Growth, BIGO Ads Up 61.5% YoY  
Mar 11, 2026 09:40 HKT/SGT
Kincora Consolidates, Commences Geophysics and Forms Partnership at Cowal East  
Mar 10, 2026 17:59 HKT/SGT
Fosun Navigates Cyclical Volatility and Clears Risks as Management Reaffirms RMB10 Bn Profit Target for Next 3 to 5 Yrs  
Mar 10, 2026 15:45 HKT/SGT
Impro Precision 2025 Profit Attributable to Shareholders Reaches Record High of HK$726.2 Million, Up 12.7% Year-on-Year, Forecast 2026 Sales Growth Rate to Accelerate to Mid-Double Digits  
Mar 10, 2026 14:19 HKT/SGT
Natural Beauty's 2025 Annual Results Show Steady & Robust Growth  
Mar 10, 2026 13:35 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575